Pharmaceuticals

Novo Nordisk AS

NVO Gains Competitive Insight from New Study Approvals

Novo Nordisk to Present New Analysis of Semaglutide ESSENCE Trial for MASH at 2026 EASL

Analysts Revise Novo Nordisk Price Targets Upwards Post-Q1 Earnings

Novo Nordisk Updates Its AMAZE 12 Phase 3 Trial for Next Wave in Obesity Maintenance Drugs

Novo Nordisk will host a Capital Markets Day on September 21, 2026

Two Pharma Companies Now Own Nearly 100% of GLP-1 Citations Inside ChatGPT, Claude and Perplexity, New 5W Index Finds

Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide

Lexaria Gains Ethics Approval for Study Comparing its Semaglutide Formulation to Novo Nordisk's Wegovy

Novo Nordisk to Hold Information Meeting

Investment firm Truffle explains its rationale for recently buying and selling Novo Nordisk stock

Novo Nordisk provides an update on its share repurchase program

Novo Nordisk to hold R&D investor event at the American Diabetes Association (ADA) 2026 meeting

Novo Nordisk Launches 15 Billion DKK Share Buyback Plan

Q1 2026 earnings analysis shows increased competitive pressure from Eli Lilly

Novo Nordisk stock falls after receiving FDA warning letter

Novo Nordisk drives oral Wegovy sales with a successful low-price, direct-to-consumer strategy

Novo Nordisk warns of significant 2026 sales decline due to pricing pressure

Legal Ozempic copy hits Canadian market

Novo Nordisk alters plan for Odense, Denmark facility, converting to storage and cutting jobs

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

Novo Nordisk A/S (NVO.US) Q1 2026 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q4 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q3 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) Q2 2025 Earnings Conference Call

Novo Nordisk A/S (NVO.US) 2024 Full Year Performance Conference Call

Novo Nordisk A/S (NVO.US) Q3 2024 Earnings Conference Call

The CDSCO has instructed states and UTs to monitor promotional activities for GLP-1 weight-loss drugs like semaglutide, following a ban on promotional activities for prescription-only therapies. The organization is enforcing compliance through audits and inspections, addressing illegal distribution and misuse. With the patent expiration of semaglutide, over 25 generic versions have emerged, prompting companies to launch multimedia campaigns focused on obesity awareness, as direct advertising is prohibited.

Business Standard

Eli Lilly

CDSCO asks states, UTs to monitor surrogate promotion for GLP-1 drugs

HBM HOLDINGS-Bannounced preclinical data for LET003, a monoclonal antibody for obesity treatment developed using AI. The results indicate LET003 has superior pharmacokinetics compared to competitors and, when combined with semaglutide, enhances fat reduction while preserving lean mass. At lower doses, it matches the effects of higher-dose bimagrumab in promoting lean mass gain, suggesting its potential as a Best-in-Class obesity therapy.

AASTOCKS News

First Trust NYSE Arca Biotech Index Fd

HBM HOLDINGS-B

HBM HOLDINGS-B  Discloses Preclinical Data of AI Candidate Drug for Obesity Treatment

Wall Street Zen upgraded Novo Nordisk A/S from a 'hold' to a 'buy' rating. This follows mixed ratings from other brokerages, with some downgrading the stock. Currently, Novo Nordisk has an average rating of 'Hold' and a consensus price target of $65.56. The stock opened at $44.71, with a market cap of $199.63 billion and a P/E ratio of 10.50. Recent earnings showed $1.03 EPS and $10.85 billion in revenue.

Market Beat

Goldman Sachs

Hims & Hers Health

Franklin Resources

T. Rowe Price

GS Hldg R

Novo Nordisk A/S (NYSE:NVO) Upgraded at Wall Street Zen

OMER

NVOX

Omeros Corporation's Q1 earnings call highlighted the successful U.S. launch of YARTEMLEA, generating $11.1 million in gross revenue. The company reported a strengthened balance sheet with $135.3 million in cash and a significant deal with Novo Nordisk worth up to $2.1 billion. Despite an adjusted net loss of $17.1 million, management expects YARTEMLEA to drive positive cash flow within 18 months. The stock has declined 38.5% since year-end 2025, raising concerns amid ongoing debt obligations.

Tip Ranks

Omeros

Defiance Daily Target 2X Long NVO ETF

Omeros Earnings Call: YARTEMLEA Launch Drives New Phase

Novo Nordisk (NOVO_B): oral Wegovy trial ECO2026/OASIS4 — early responders (≈33%) lost 13.2% at 4 months, 21.6% at 64 weeks; overall treatment 17% vs placebo 2.7%.12Novo Nordisk (NOVO_B) and Rexall partner to deliver Ozempic and Wegovy to Canadian patients' homes, offering home delivery, in-store pricing and patient support—key operational updates for traders.3

TradingView

Key facts: Novo Nordisk early −21.6% 64w; Rexall delivery Canada

Novo Nordisk (NYSE:NVO) has delivered an annualized return of 29.58% over the past 15 years, outperforming the market by 17.52%. With a current market capitalization of $208.88 billion, a $100 investment in NVO stock 15 years ago would now be worth $4,873.71, highlighting the significant impact of compounded returns on investment growth.

benzinga_article

Here's How Much $100 Invested In Novo Nordisk 15 Years Ago Would Be Worth Today

Novo Nordisk presented new data on its Wegovy pill at the European Congress on Obesity 2026, showing significant long-term weight loss and improved physical function. Participants who lost at least 10% of body weight by week 16 achieved an average weight loss of 21.6% by week 64. The Wegovy pill also demonstrated better outcomes compared to orforglipron, with lower discontinuation rates due to gastrointestinal side effects. Novo Nordisk shares were down 0.11% at $46.95, but have gained 26.4% over the past month.

S&P 500

Novo Nordisk Highlights New Wegovy Pill Data

Novo Nordisk AS(NVO.US)